Device Trial Radar · NCT07279142
Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 16, 2025
Primary completion
Nov 13, 2026
Study completion Dec 24, 2026
Sponsor
- Lead sponsor
- IRCCS San RaffaeleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Campania Luigi Vanvitelli
- First posted
- Dec 12, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigator hypothesizes that controlled delivery of low heat (45-50 Centigrade) to the sub-detrusor and detrusor muscle can ablate the autonomic nerve endings and control overactive bladder symptoms without causing significant damage to the surrounding structures. Low heat in such a manner is below urethral sensation and enables office treatment. The transvaginal approach is non-invasive and improves overactive bladder (OAB) symptoms and patients' quality of life. The investigator believes that the RF administration results could be equal or better for first-line treated patients compared to pharmacological refractory patients.
Conditions
- Overactive Bladder (OAB)
- Incontinence, Urge
Interventions
RadiofrequencyDevice
According to the study protocol, eligible subjects will receive one treatment within 3 weeks of screening. After one month, if there is no satisfactory result, a second treatment will be administered, and after another month, the patient will be evaluated. If there is still no end point, a third treatment will be given. It should be noted that the second and third treatments will only be performed if there is no satisfactory result after the previous treatment. Treatment area: Treatment area will include vaginal canal. Treatment Procedure: * Subjects receive HYPNOS treatment with device using radiofrequency (RF). Treat vaginal canal at the depth starting from approximately 3.5cm from introitus to the distal end of vagina. Radially the treatment area is from 9 to 3 o'clock. * Patient should empty bladder prior to treatment * Position patient in lithotomy position * Set energy to levels well tolerated by the subject. Suggested settings: Burst Mode 7mm, 1 pass.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement of 40% in the Overactive Bladder Symptoms Bother Questionnaire Score Short Form from the baseline scoreTime frame: From enrollment to 12 weeks after last treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IRCCS Ospedale San Raffaele
Milan, Italy, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.